Chiusura precedente | 2,5400 |
Aperto | 2,5200 |
Denaro | 2,3500 x 100 |
Domanda | 2,3700 x 1100 |
Min-Max giorno | 2,3200 - 2,5250 |
Intervallo di 52 settimane | 2,2300 - 6,0500 |
Volume | |
Media Volume | 2.289.668 |
Capitalizzazione | 490,642M |
Beta (mensile su 5 anni) | 0,86 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,7800 |
Prossima data utili | 31 lug 2024 - 05 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 11,51 |
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company’s financial operations and business strategy and will serve as a member of the Leadership Team. “Geoff’s extensive experience in biotechnology across all
Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive Host Immune CellsEvaluation of Cloak™ Technology to Engineer Allogeneic Cells from Detection by the Host Immune System Preclinical Validation of ALLO-182, an AlloCAR T™ Candidate Targeting Claudin18.2 for the Treatment of Gastric and Pancreatic Cancers SOUTH SAN FRANCISCO,
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in an upcoming investor conference in September. Baird 2023 Global Healthcare ConferenceTuesday, September 12, 202312:45PM PT/3:45PM ET Any available webcasts will be posted to the Company's website at www.allogene.com under the In